Share Price:

APNASPENAspen Pharmacare Hldgs16630-129 (-0.77%)

Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.

Aspen delivers strong results and advances its strategic ambitions

Stephen Saad Aspen Group Chief Executiv

Aspen Pharmacare Holdings has reported positive Group interim financial results for the six months ended 31 December 2024.

Aspen’s revenue increases 10% underpinned by a strong second half performance

Stephen Saad Aspen Group Chief Executiv

JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.

Aspen building momentum with revenue up 10% to R21,1 billion

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid unaudited interim Group financial results for the six months ended 31 December 2023. SALIENT HIGHLIGHTS Revenue increased by 10% (2% in constant exchange rate (“CER”)) to R21,1 billion (December 2022: R19,2 billion) Normalised EBITDA increased by 2% (-5%… Continue reading Aspen building momentum with revenue up 10% to R21,1 billion

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.